Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA - Herbst, R S; Tsuboi, M; John, T (Poster Abstract Congress of the American Society of Clinical Oncology Journal (ASCO), 2020)
38(18_suppl): LBA5-LBA5